Search Results | Litt's Drug Eruption and Reaction Database

Drugs belonging to

class – Phosphodiesterase type 5 (PDE5) inhibitor – 4 items found

Avanafil Compare:

Sildenafil Compare:

Tadalafil Compare:

Vardenafil Compare:

Adverse reactions attributed to entire drug class 'Phosphodiesterase type 5 (PDE5) inhibitor'

Please login to view adverse reactions.

Flushing / rubefaction

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]
(2016): Gao L+, Int J Gynaecol Obstet 133(2), 139 [Review]
(2016): Jia DD+, Spinal Cord 54(7), 494 [Review]
(2012): Rizio N+, J Spinal Cord Med 35(4), 219 [Review]

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]

Epistaxis (nosebleed)

(2016): Vlastarakos PV+, J Emerg Med 51(5), e103

Nasal congestion

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]

(2024): Miyata K+, J Med Invest 71(1.2), 134-140 (aneurysm / arterial dissection association) (pharmacovigilance / pharmacoepidemiology)

(2012): Rizio N+, J Spinal Cord Med 35(4), 219 (mild) [Review]

Cranial neuropathy (includes types of palsy)

(2015): van Landingham SW+, Am Orthopt J 65, 109-14 (1 case)

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]
(2016): Gao L+, Int J Gynaecol Obstet 133(2), 139 [Review]
(2016): Jia DD+, Spinal Cord 54(7), 494 [Review]
(2012): Rizio N+, J Spinal Cord Med 35(4), 219 [Review]

Vertigo / dizziness

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]

Dyspepsia / functional dyspepsia (indigestion) (see also gastroparesis)

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]

Myalgia/Myositis/Myopathy/Myotoxicity

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]

Abnormal vision

(2017): Scaglione F+, Clin Ther 39(2), 370 [Review]

Glaucoma (includes acute angle-closure glaucoma)

(2019): Baker JC+, Drugs Aging 36(11), 991-997 (associated risk factors)

Ocular adverse effect

(2021): Barroso F+, J Ophthalmic Vis Res 16(2), 248-259 [Review]
(2011): Azzouni F+, J Sex Med 8(10), 2894-903 [Review] (association) (Naranjo Adverse Drug Reaction Probability Scale or equivalent)

Optic neuropathy (includes ischemic optic neuropathy)

(2018): Yafi FA+, Sex Med Rev 6(2), 242 [Review]

Visual disturbances

(2016): Gao L+, Int J Gynaecol Obstet 133(2), 139 [Review]

Pulmonary hypertension

(2021): Turner JM+, Am J Obstet Gynecol Jun, Online ahead of print [Review] (increased risk)

Rhinitis / rhinosinusitis (see also sinusitis)

(2022): Alromaih S+, Ear Nose Throat J Nov, Online ahead of print [Review]

Adverse effects / adverse reactions

(2023): Shin YE+, Sex Med 11(5) (e-Collection) (pharmacovigilance)
(2016): Jiang R+, Zhonghua Nan Ke Xue (Chinese) 22(2), 99 [Review]

Fetal adverse effect

(2024): Liu Y+, J Pharm Pharm Sci Aug (e-Collection) [Review]

(2021): Turner JM+, Am J Obstet Gynecol Jun, Online ahead of print [Review] (increased risk)

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere